termination of the zygosity of the RhD-positive father can aid in the assessment of a couple's risk of carrying a RhD-positive offspring, particularly in the case of preconception counseling of RhD-negative mothers immunized from a previous pregnancy. For example, heterozygous males have a 50% chance of producing a RhD-negative offspring, in which case the pregnancy will not be at risk for HDN. On the other hand, homozygous RhD-positive males can produce only RhD-positive offspring, and therefore, close monitoring of the pregnancy is needed.
At present, determination of RhD zygosity in RhDpositive individuals is commonly inferred from results of serological testing, firstly, because the currently available molecular methods, such as single-sperm analysis, microsatellite analysis, and other gel-based electrophoretic techniques (4 -7 ) , are either too labor-intensive or technically demanding for routine use, and secondly, because the genetic structure of the prevalent RHD deletion in Caucasians had not been elucidated until recently (8 ) , further assay development for zygosity determination has been hampered by the lack of reference assays that could reliably and accurately determine RHD genotype. Consequently, reliable and robust methods for RhD zygosity determination have been lacking.
Recently, Wagner and Flegel (8 ) elucidated the genetic structure of the RH locus and characterized the location of the RHD deletion that is responsible for the majority of RhD-negative phenotypes in Caucasians. Such sequence information allows development of assays for the specific detection of the RHD deletion, which previously was not possible. We have developed two approaches for the determination of RhD zygosity. The first assay, which is based on the work of Wagner and Flegel (8 ) , relies on specific detection of the RHD deletion through amplification of a 1507-bp fragment by a double Amplification Refractory Mutation System (double ARMS) approach (9 ) . In addition, in view of the need for a rapid, robust, and automatable assay adaptable for routine laboratory testing, we have developed a second assay for determination of RhD zygosity. This assay is based on a multiplex real-time quantitative PCR approach through amplification and quantification of RHD sequences in relation to a reference gene, albumin. The reliability of this assay has been assessed by comparison with the double ARMS assay.
Materials and Methods subjects
Blood (5 mL) was collected from 46 blood donors into EDTA tubes. Ethics approval was obtained from the Central Oxford Research Ethics Committee. The blood samples were subjected to full Rh phenotyping for D, C, c, E, and e antigens, performed by the National Blood Service, Oxford, United Kingdom. Ten of the subjects were RhD-negative, and the remaining subjects were RhD-positive; 18 of the RhD-positive subjects tested homozygous and the others heterozygous for RhD. The method of Rh phenotyping consisted of serological methods with calculation of the most probable Rh genotype from known frequencies of Rh genotypes in an English population (10 ) .
After collection, the blood samples were centrifuged at 1600g for 10 min, and the plasma was removed. The buffy coat was stored at Ϫ20°C until further processing. DNA was extracted from the buffy coat (200 L) with the Nucleon reagent set (Amersham Life Science) according to the "blood and cell culture 2 (BACC2)" protocol recommended by the manufacturer.
All of the primers used in this study were synthesized by Life Technologies.
double arms approach
Allele-specific primers were designed to detect the RHDdeleted allele by a double ARMS approach (9 ) . The double ARMS approach involves the use of two allelespecific primers simultaneously during PCR when there is a need to distinguish a sequence of interest from two or more closely related sequences. According to Wagner and Flegel (8 ) , 5Ј and 3Ј to the RHD gene there are two highly homologous DNA segments, designated "Rhesus boxes", which are ϳ9000 bp in length (Fig. 1A) . The two Rhesus boxes share 98.6% homology within which there is a segment of 1463 bp, termed the "identity region", where the sequence is completely identical. For the most prevalent RhD-negative haplotype in Caucasians, the breakpoints of the RHD deletion are located within the identity region of the Rhesus boxes. Consequently, in the RhDnegative haplotype, only one Rhesus box was found, which is of a hybrid nature, comprising the 5Ј end of the Rhesus box upstream to the RHD gene and the 3Ј end of the downstream Rhesus box.
We exploited the differences in the DNA sequences of the upstream, downstream, and hybrid Rhesus boxes and designed double ARMS primers that specifically amplify hybrid one, and therefore detect the RHD-deleted allele (Fig. 1B) . The forward and reverse primers were designed to anneal to the 5Ј and 3Ј ends of the 1463-bp identity region. At the 5Ј end of the identity region, the downstream Rhesus box differs by 1 bp in sequence from the upstream and hybrid Rhesus boxes. The last base pair of the forward primer, HYB2-U, matches the sequence of the upstream and hybrid Rhesus boxes, but not the downstream one. The reverse primer, HYB2-L, was designed to anneal to the 3Ј end of the identity region, where there is a 1-bp insertion in the upstream Rhesus box compared with the downstream and hybrid Rhesus boxes. The reverse primer sequence matches that of the hybrid and downstream Rhesus boxes, but not the upstream one. Consequently, the primers selectively amplify a 1507-bp segment of the hybrid Rhesus box. To enhance the specificity of the primers, an additional mismatch was introduced into the third base pair from the 3Ј end of both primers (Fig. 1B) .
PCR amplification reactions were set up according to the manufacturer's (Applied Biosystems) instructions in a reaction volume of 50 L. DNA (100 ng) was added to each reaction mixture, which consisted of 5 L of 10ϫ buffer II; 300 nM each amplification primer; 200 nM each of dATP, dCTP, dGTP, dTTP; 4 mM MgCl 2 , and 2.5 U of AmpliTaq Gold. PCR was carried out in a MJ Research PTC-200 thermal cycler (MJ Research) with a thermal profile that started with a first denaturation step of 2 min at 95°C, followed by 40 cycles of 95°C for 1 min, annealing at 50°C for 1 min, and extension at 72°C for 5 min, with a final step of 72°C for 10 min. The PCR products were visualized on 1% agarose gels with ethidium bromide staining.
multiplex real-time quantitative pcr
A multiplex real-time quantitative PCR-based assay has been developed for the homogeneous detection of RhD zygosity. This assay is based on the amplification and quantification of RHD sequences in relation to a reference gene, albumin, in a single PCR. The RHD TaqMan system consists of the amplification primers RD-A and RD-B, as well as the dual-labeled fluorescent probe RD-T, as described previously (11 ) . Similarly, the albumin system consists of the primers Alb-up (5Ј-GCTGTCATCTCT-TGTGGGCTGT-3Ј), Alb-low (5Ј-ACTCATGGGAGCTG-CTGGTTC-3Ј), and the Alb-probe [5Ј(JOE)-CCTGTCA-TGCCCACACAAATCTCTCC-(TAMRA)3Ј, where JOE is 2,7-dimethoxy-4,5-dichloro-6-carboxyfluorescein, and TAMRA is 6-carboxytetramethylrhodamine. The primers and probe were synthesized according to Laurendeau et al. (12 ) , although the probe was synthesized in the reverse sense. The dual-labeled fluorescent probes were synthesized by Applied Biosystems, and each contained a 5Ј reporter dye, 6-carboxy-fluorescein (FAM) and JOE, respectively, and a 3Ј quencher, TAMRA. The different spectral characteristics of the reporter dyes, FAM and JOE, enable each amplification system to be monitored independently.
Multiplex amplification reaction mixtures were set up in a reaction volume of 50 L. All components other than the primers and probes were supplied in a TaqMan PCR Core reagent set (Applied Biosystems). DNA (100 ng) was added to each reaction mixture, which consisted of 5 L of 10ϫ buffer A; 300 nM each amplification primer (RHD and albumin); 62.5 nM RD-T probe; 100 nM Alb-probe; 3 mM MgCl 2 ; 200 nM each of dATP, dCTP, dGTP; 400 nM dUTP; 1.25 U of AmpliTaq Gold; and 0.5 U of AmpErase uracil N-glycosylase. The following thermal profile was used: 2 min incubation at 50°C, followed by a first denaturation step of 10 min at 95°C, then 40 cycles of 95°C for 15 s and 60°C for 1 min.
Real-time quantitative PCR was carried out in an Applied Biosystems 7700 Sequence Detector. The theoretical and practical aspects of this technology have been described in detail elsewhere (13 ) . The amplification and product-reporting systems used are based on the 5Ј nuclease assay, in which the liberation of a fluorescent reporter, tagged onto a sequence-specific probe, is coupled to the amplification reaction (14 ) . The sequence detector monitors the increase in fluorescent signal of each reaction well and determines the number of amplification cycles required to reach a fixed threshold signal intensity, termed the threshold cycle (Ct), which is recorded by the 7700 Sequence Detection Software (Ver. 1.6.3). The Ct is inversely proportional to the logarithmic scale of the starting quantity of template DNA. Consequently, the gene dosage at a particular gene locus, e.g., RHD in this study, can be deduced by calculating the difference in Ct from the Ct of a reference gene, e.g., albumin, termed ⌬Ct (15 ) . Thus:
where Ct(RHD) denotes the Ct value of the RHD PCR, and Ct(albumin) denotes the Ct value of the albumin PCR.
The average analysis time, including blood component separation and DNA extraction, was 3 h.
statistical analysis
Descriptive statistics were carried out using SigmaStat 2.0 software. To determine the discriminating power of the multiplex real-time PCR assay for RhD-positive homozygotes from heterozygotes, the mean ⌬Ct and its standard deviation for the homozygotes and heterozygotes were calculated. The 99% confidence interval for the difference between the ⌬Ct values of the heterozygous and homozygous cases is given by the following equation: 
Results

double arms pcr assay
In the double ARMS approach, RhD-negative samples were analyzed as controls to indicate positive amplification of the RHD-deleted allele. Among the RhD-positive samples, the hybrid Rhesus box should be amplifiable only in the heterozygous state because these individuals have inherited one allele containing the RHD deletion. The RhD-positive samples were analyzed, and the results were in complete concordance with serological typing. As expected, PCR products were observed only in RhDnegative and heterozygous RhD-positive samples, but not in the homozygous RhD-positive samples.
multiplex real-time quantitative pcr assay
For the real-time quantitative PCR approach, RHD-specific sequences were amplifiable only from RhD-positive samples and not from the RhD-negative samples. ⌬Ct values were calculated for the RhD-positive samples. The ⌬Ct values obtained clearly segregated into two distinct populations (Fig. 2) , with mean ⌬Ct values of 1.70 (SD, 0.17) and 2.62 (SD, 0.29) for the homozygous and heterozygous samples, respectively (P Ͻ0.001, t-test) . The distinction between the homozygous and heterozygous RhD-positive samples was in complete concordance with typing by both the serological and double ARMS assays. The larger numerical values obtained for the heterozygous samples were as expected and reflected the smaller RHD gene dosage in these samples, producing a larger difference between the Ct(RHD) and the Ct(albumin).
The mean difference in the ⌬Ct values of the heterozygous and homozygous samples was 2.62 Ϫ 1.70 ϭ 0.92. The pooled SD was 0.057. The 99% confidence interval for the mean difference in the ⌬Ct values of the heterozygous and homozygous samples was 0.77-1.07, which did not straddle the value of 0. In other words, the real-time PCR assay had at least a 99% chance of distinguishing a heterozygous from a homozygous RhD-positive individual.
Discussion
Despite modern obstetrical practices and the availability of Rh immunoglobulin, Rh incompatibility remains the leading cause of HDN. HDN occurs when a previously sensitized RhD-negative pregnant woman conceives a RhD-positive fetus. A noninvasive prenatal test is now available for assessment of the fetal RhD status based on the detection of fetal-derived RHD sequences in maternal plasma (11 ) . However, the sensitivity of this assay is reduced during the first trimester because the concentration of fetal DNA in maternal plasma is relatively low during this period (11, 16 ) . Consequently, RhD zygosity determination of the RhD-positive father provides useful information for risk estimation during preconception counseling or early pregnancy. Wagner and Flegel (8 ) have elucidated the site of the most prevalent RHD deletion in Caucasians and developed two PCR-based assays for the specific detection of the RHD deletion. The assays described include a longrange PCR assay, which relies on the amplification of a 9416-bp fragment that is amplifiable only in the RHDdeleted allele, and a PCR-restriction fragment length polymorphism assay for amplification of a 3100-bp fragment with subsequent PstI digestion. However, both assays have several shortcomings. The long-range PCR requires relatively difficult optimization, whereas the PCR-restriction fragment length polymorphism assay relies on post-PCR enzyme digestion and interpretation of the restriction pattern. Conversely, the amplification of a 1507-bp segment of the hybrid Rhesus box using the double ARMS approach described in this study can robustly and accurately distinguish heterozygous from homozygous RhD-positive genotypes.
In Caucasians, a complete deletion of RHD is the most common cause for lack of expression of the D antigen, whereas the remaining cases are the result of structural abnormalities in the RHD gene, where the gene is often amplifiable. Consequently, such RHD-positive D-antigennegative alleles cannot be accurately determined by tests for RhD genotyping based on direct detection of the RHD deletion. However, a recent study has shown that such mutations occur very rarely (17 ) . In Caucasians, ϳ6% of RhD-negative but C-or E-positive individuals, and 0.03% of individuals with cde haplotypes are found to have amplifiable RHD. Consequently, when such values are combined with the frequency of occurrence of the various RhD-negative haplotypes (10 ) , it can be estimated that among Caucasians, RHD is amplifiable in Ͻ0.4% of RhDnegative alleles. In other words, 99.3% of RhD-negative alleles can be correctly typed by direct detection of the RHD deletion.
In addition to the direct detection of the RHD deletion as described above, many alternative approaches have been used for the determination of RhD zygosity, including single-sperm analysis, microsatellite analysis, and other gel-based electrophoretic techniques (4 -7 ) . Compared with these techniques, the real-time quantitative PCR approach has much reduced risk of contamination because it is a homogeneous assay, requiring no post-PCR processing. In addition, it is less labor-intensive, more robust, and automatable. The results are clearly presented in a numerical format that can be easily interpreted. Coupled with a short turnaround time, the approach can potentially be used by any routine laboratory for highthroughput analysis. An advantage of this multiplex approach is that the albumin system also acts as an internal amplification control in addition to being the reference gene for gene dosage calculation. This design also allows for the simultaneous determination of RhD-negative, RhD-positive homozygous and heterozygous genotypes in a single assay.
In conclusion, we have developed two assays for determination of RhD zygosity. The double ARMS approach is based on direct detection of the RHD deletion, whereas the multiplex real-time quantitative PCR assay is based on RHD gene dosage comparison with the reference gene, albumin. The results of both assays are concordant with each other as well as with the serology-based method. The real-time quantitative PCR can be adapted for highthroughput determination of RhD zygosity in a routine setting. It is hoped that the availability of tests for assessing RhD zygosity will lead to better management of sensitized RhD-negative pregnant women.
